This page shows the latest STING news and features for those working in and with pharma, biotech and healthcare.
Mersana’s proprietary Immunosynthen STING-agonist ADC platform generates systemically administered ADCs that locally activate STING signalling in both tumour-resident immune cells and antigen-expressing tumour cells, unlocking the ... This
combinations. The STING pathway plays a critical role during infections and autoimmune disease, as well as one of the key innate immunity pathways responsible for antitumour immunity. ... The therapeutic targeting of STING is therefore seen as a
started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.
Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015. ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop small-molecule STING agonists.
BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
salve its sting.
More from news
Approximately 2 fully matching, plus 20 partially matching documents found.
This will help to take the financial sting out of the price of preparation.
Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can
It’s like deconstructing a joke; by the end, the punchline loses its sting.
825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
And the sting in the tail? The impact of COVID-19. Patients not presenting with symptoms, delays in diagnostics, delays in treatments…analysts suggesting that any progress being made on survival
patients over the next few decades may have a sting in the tail.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...